UROPLAKIN II AS A PROMISING MARKER FOR MOLECULAR DIAGNOSIS OF NODAL METASTASES FROM BLADDER CANCER: COMPARISON WITH CYTOKERATIN 20
- 1 December 2005
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Journal of Urology
- Vol. 174 (6), 2138-2143
- https://doi.org/10.1097/01.ju.0000181214.32390.75
Abstract
Purpose: Current methods used to determine pathological examination of the lymphatics after radical cystectomy are tedious and costly. We performed a systemic study of uroplakin II (UP II) and cytokeratin 20 (CK 20) expression in pelvic lymph nodes on multiple sides in patients with bladder cancer. Materials and Methods: A total of 82 pelvic lymph node and 19 bladder tumor samples were obtained from 21 patients with bladder cancer by radical cystectomy with pelvic lymphadenectomy for reverse transcriptase-polymerase chain reaction assay. Results: Of the 19 bladder tumor tissue specimens 19 (100%) and 13 (68.4%) were positive for UP II and CK 20 mRNA expression, respectively. UP II mRNA was detected in 15 of 16 pelvic lymph node samples (93.8%) with pathologically proven metastases, whereas 9 (56.6%) were positive for CK 20 mRNA. The reverse transcriptase-polymerase chain reaction assay for UP II was statistically more sensitive than that for CK 20 in detecting not only primary tumors, but also metastatic pelvic lymph nodes (p = 0.0179 and 0.0373, respectively). Of 66 pelvic lymph node samples without metastasis UP II was detected in 6 (10%), while CK 20 was not. In addition, UP II and CK 20 mRNA could be detected in at least 50 and 500 bladder cancer HT1197 cells, respectively. Conclusions: These results indicate that UP II might be a more useful marker than CK 20 for detecting micrometastases of bladder cancer in the pelvic lymph nodes, although a greater number of patients and longer followup are needed to come to a definitive conclusion.Keywords
This publication has 13 references indexed in Scilit:
- Radical Cystectomy for Bladder Cancer Today—A Homogeneous Series Without Neoadjuvant TherapyJournal of Clinical Oncology, 2003
- Cytokeratin 7 and 20 staining for the diagnosis of lung and colorectal adenocarcinomaBritish Journal of Cancer, 2002
- Prognostic Significance of Cytokeratin-20 Reverse Transcriptase Polymerase Chain Reaction in Lymph Nodes of Node-Negative Colorectal Cancer PatientsJournal of Clinical Oncology, 2002
- Detection of Disseminated Medullary Thyroid Carcinoma Cells inCervical Lymph Nodes by Cytokeratin 20 Reverse Transcription‐PolymeraseChain ReactionWorld Journal of Surgery, 2002
- Increased intracellular doxorubicin by anti-Fas monoclonal antibody: a mechanism that enhances the cytotoxicity in renal cell carcinoma cellsUrology, 2001
- Cytokeratin-20 reverse-transcriptase polymerase chain reaction as a new tool for the detection of circulating tumor cells in peripheral blood and bone marrow of bladder cancer patients.European Urology, 2001
- DETECTION OF CIRCULATING UROPLAKIN-POSITIVE CELLS IN PATIENTS WITH TRANSITIONAL CELL CARCINOMA OF THE BLADDERJournal of Urology, 1999
- Detection of colorectal carcinoma cells in circulating peripheral blood by reverse transcription-polymerase chain reaction targeting cytokeratin-20 mRNALife Sciences, 1997
- The role of pelvic lymphadenectomy and radical cystectomy for lymph node positive bladder cancer. The memorial sloan-kettering cancer center experienceCancer, 1994
- Identification of protein IT of the intestinal cytoskeleton as a novel type I cytokeratin with unusual properties and expression patterns.The Journal of cell biology, 1990